Orexigen Therapeutics Price / Sales Ratio: 32.95
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
OREX Price / Sales Ratio Rankings
| Overall | 1st percentile | 4319 of 4365 |
| Sector | 6th percentile | 427 of 457 in Healthcare |
| Industry | 7th percentile | 35 of 38 in Drug Manufacturers - Other |
About Price to Sales Ratio
The price to sales ratio (PS ratio) is calculated by dividing stock price by the revenue per share. It is most useful for comparing companies within a sector or industry because "normal" values for this ratio vary from industry to industry. In general, low price to sales ratios are more appealing because they suggest that a company is undervalued.
An example illustrating why PS ratios should not be compared across industries: On June 21, 2010, Starbucks had a PS ratio of 1.12 while Yahoo! had a PS ratio of 2.56. In other words, Yahoo! shareholders were paying $2.56 for $1 of sales while Starbucks shareholders would only pay $1.12 for $1 of sales. However, at that same moment, the two companies' price to earnings ratios were virtually identical (Starbucks: 28.09 and Yahoo!: 27.78). Hence, shareholders were paying nearly the same amount for $1.00 in earnings. The PS ratios, though, are less comparable since Yahoo!'s profit margins are much higher than that of Starbucks.
Learn More
You may also be interested in these OREX related companies
OREX News
RT @BioRunUp $OREX up 15%+ to $3.20 on SPA news. Thats awesome.... if you want to wait for 2.5 years for the study to be completed.
about 6 days ago by swingtrades99
about 6 days ago by swingtrades99
$OREX Upside Blowoff - 15 Minute Down Reversal - Red bar after 4 green bars with higher highs and higher lows
about 6 days ago by TradeIdeasQuant
about 6 days ago by TradeIdeasQuant
Orexigen® Announces Agreement From the FDA on a Special Protocol Assessment for the Contrave® Outcomes Trial
Feb 06, 8:00AM PR Newswire
Feb 06, 8:00AM PR Newswire
@EXPstocktrade $orex up 10% today (20%) in a week. News releases coming soon
about 18 days ago by behconsult
about 18 days ago by behconsult
@EXPstocktrader FYI -I no u r busy- update only $orex up 7% on high vol- something is cooking
about 23 days ago by behconsult
about 23 days ago by behconsult
@EXPstocktrader Will watch for cup & handle and pping $orex. Today 3x volume up and 5.5%
about 23 days ago by behconsult
about 23 days ago by behconsult
@Drew_Yoshida $orex insider were "purchases" as opposed to "aquire" or exercised option
about 25 days ago by behconsult
about 25 days ago by behconsult
$OREX may be forming a cup and handle...watch for a drop...the handle... then ping me someone
about 25 days ago by EXPstocktrader
about 25 days ago by EXPstocktrader
@EXPstocktrader $orex biotech rumor takeover 1 yr now. Recent large insider purchase by several- a 1st for company hx. Crs 200 dy on radar
about 25 days ago by behconsult
about 25 days ago by behconsult
$Orex biotech rumor takeover for about 1 year. Recent larger insider purchase by several- a first for company. Cross 200 day cheap- on radar
about 25 days ago by behconsult
about 25 days ago by behconsult
$OREX 200 Day SMA Cross - Price crossed above 200 day SMA (2.0277). Confirmed by volume.
about 31 days ago by TradeIdeasQuant
about 31 days ago by TradeIdeasQuant
Orexigen Therapeutics to Present at the J.P. Morgan Healthcare Conference
Jan 05, 8:00AM PR Newswire
Jan 05, 8:00AM PR Newswire
QVT Financial Raises Stake in Orexigen Therapeutics, Inc. (OREX) to 9.82%
Dec 27, 9:22AM Street Insider
Dec 27, 9:22AM Street Insider
Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock
Dec 22, 4:00PM PR Newswire
Dec 22, 4:00PM PR Newswire
Orexigen® Therapeutics Prices Public Offering of Common Stock and Warrants to Purchase Common Stock
Dec 15, 9:22AM PR Newswire
Dec 15, 9:22AM PR Newswire
Orexigen Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
Dec 14, 5:25PM Benzinga
Dec 14, 5:25PM Benzinga
Orexigen Therapeutics to Present at the Lazard Capital Markets Healthcare Conference
Nov 11, 8:00AM PR Newswire
Nov 11, 8:00AM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| OREX | 3.03 | -0.08 | -2.57% | 145.68M |
| YHOO | 16.14 | 0.14 | 0.88% | 20.02B |
| JNJ | 64.60 | -0.29 | -0.45% | 176.41B |
| LZB | 13.79 | -0.23 | -1.64% | 717.91M |
| ASBC | 12.67 | -0.24 | -1.86% | 2.21B |
| JLL | 81.45 | -0.34 | -0.42% | 3.54B |
| TRN | 33.14 | -0.45 | -1.34% | 2.66B |
| CMG | 376.45 | -0.04 | -0.01% | 11.78B |
| PRX | 36.55 | -0.50 | -1.35% | 1.33B |
| DV | 38.56 | -0.28 | -0.72% | 2.59B |
